2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Research, AML, MDS, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4292 Optimizing practice ensures engraftment, low NRM and high disease-free survival in adult double unit cord blood transplant recipients with high-risk AML

Katya F Ahr, MD, MA, Joshua A Fein, MD2, Ioannis Politikos, MD3, Sarah Samorodnitsky, PhD4, Yushu Shi, PhD5, Stephanie Chinapen6, Sean Quach7, Amethyst Saldia8, Pamela Susman, MS9, Ann Jakubowski, PhD, MD10, Esperanza Papadopoulos, MD11, Miguel-Angel Perales, MD12, Roni Tamari, MD13, Parastoo B. Dahi, MD14, Candice Rapoport15, Deborah Wells16, Alexandra Gomez-Arteaga, MD17, Nora Chokr, MD18, Sebastian Mayer, MD19, Amer Assal, MD20, Tsiporah Shore, MD21, Anne Archer22, Tenzin Yingsal23, Andromachi Scaradavou, MD24, Doris M Ponce, MD25, Juliet Barker, MB, BS26
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
18 Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
19 Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
20 Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
21 Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
22 Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
23 Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
24 Memorial Sloan Kettering Cancer Center, New York, New York, United States
25 Memorial Sloan Kettering Cancer Center, New York, New York, United States
26 Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States

Introduction: Many reports from US and international cord blood transplant (CBT) centers demonstrate high disease-free survival in younger adult and pediatric patients (pts) with high-risk leukemias when best practices are used. CBT has declined, however, especially in adults. This may compromise transplant access for pts lacking suitable, readily available adult donors. To evaluate the efficacy of contemporary CBT in adults, we evaluated outcomes from two CBT centers, one established and one more recently implementing a double-unit CBT (dCBT) program.

Methods: dCBT outcomes in adult recipients of intermediate-intensity myeloablative, ATG-free “midi” conditioning using cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg, TBI 400 cGy with cyclosporine-A/mycophenolate mofetil at 2 centers were analyzed. Adult pts underwent midi dCBT as of 2021 (Center 1) and 2023 (Center 2) incorporating optimized unit selection, thaw, infusion and supportive care practices (including omission of ATG) per 2020-2021 ASTCT guidelines. Patients with active acute leukemia were excluded. GVHD diagnosis was based on clinical presentation and graded by MAGIC (acute) and NIH (chronic) criteria.

Results: Center 1 pts (n=40) underwent dCBT from 3/2021-6/2025 (median survivor follow-up 42 months, range 12-62). Median age was 39 years (range 23-62), 23% had HCT-CI >3 and 48% were of non-European ancestry, with most (n=21) transplanted for AML (12 MRD+, 12 ELN 2022 adverse risk). Other diagnoses included 8 ALL (all MRD-), 6 MDS, 4 MPAL. Median cell doses of the 80 units were 2.3 x107kg TNC/unit and 1.6 x105kg viable CD34+/unit; median unit-recipient 8-allele HLA-match was 5/8 (range 3-6/8). All patients engrafted neutrophils (median 19 days, range 13-36) and platelets (median 37 days, range 26-92). Day 180 grade II-IV aGVHD incidence was 90% (95%CI 73-96) with 13% (95%CI 5-25) grade III-IV aGVHD. By 3 years, 2 patients had mild cGVHD. NRM incidence at 3-years was 5% (95%CI 9-16). While incidence of relapse was 24% (95%CI 11-40), there was a notable difference by pt diagnosis: only 2 of 21 AML pts relapsed (1/12 MRD+ pts), 1/6 MDS pts and none with MPAL, however, 4/8 ALL pts relapsed over 5-years of follow-up. 3-year OS and PFS were 87% (95%CI 78-98) and 74% (95%CI 62-89), respectively.

By comparison, Center 2 dCBT pts (n=14) transplanted 9/2023-6/2025 had a shorter 22 month (range 9-33) median survivor follow-up (1 lost to follow-up at 9 months) but similar median age (41 years, range 21-60) and HCT-CI distribution (21% >3). However, over three-quarters (79%) were of non-European ancestry. Most (n=9) had AML (4 MRD+, 6 ELN 2022 adverse risk); other diagnoses included 2 ALL (1 MRD+), 1 MDS (biallelic TP53mut), 1 myeloid sarcoma, 1 BPDCN with residual disease. Median cell doses of 28 units were higher (3.1 x 107/kg TNC/unit, 2.3 x 105/kg CD34+/unit) and units were more HLA-mismatched (median 4/8, range 3-6/8). Like Center 1, all patients engrafted neutrophils (median 19 days, range 12-32) and platelets (median 37 days, range 28-60) at similar speeds, only 2 patients had mild cGVHD and NRM was very low (0% at 2-years). While day 180 incidence of grade II-IV aGVHD was 57% (95%CI 30-85), grade III-IV aGVHD was higher at 36% (95%CI 9-62). Except for the TP53 mutated MDS pt, all pts are in remission (including 4 MRD+ AML), for a 2-year relapse incidence of 8% (95%CI 0-23). As with Center 1, high OS and PFS were observed, both 89% (71-100); 2-yr PFS in acute leukemia pts was 100%.

Conclusion: In younger adults with relatively low comorbidity burden, optimized intermediate-intensity ATG-free dCBT is associated with very high survival in AML pts regardless of MRD status or high-risk disease. Use of optimal CBT practices ensures engraftment with very low rates of cGVHD and NRM. Severe aGVHD can be a limitation as observed in the predominantly non-European ancestry Center 2 pts, potentially explained by greater HLA-mismatch, adverse socioeconomic factors and differences in aGVHD management. Nonetheless, the “off-the-shelf” graft availability combined with very low NRM and relapse in high-risk myeloid diseases makes dCBT an important alternative for this population. Dedicated phase II trials investigating dCBT in high-risk myeloid diseases, alternative GVHD prophylaxis strategies to mitigate severe GVHD without abrogating GVL, and novel less-intense conditioning to extend dCBT to older pts are warranted.

Katya F Ahr, MD, MA: No relevant conflicts of interest to declare.